This is One North Stories, an A*START CENTRAL PodcastRegenerative medicine to cure diabetes?  BetaLife is working to make that a reality.  A spin-off the Institute of Molecular and Cell Biology (IMCB), A*STAR,  BetaLife is developing cell replacement therapy using human induced pluripotent stem cell (hiPSC) based pancreatic beta cells – cells in our body that secrete insulin. This technology could dramatically transform and improve the lives of diabetes patients who are highly dependent on insulin injections. This therapy is targeted as a curative treatment for Type 1 diabetes, other forms of insulin-dependent diabetes, as well as a treatment option for Type 2 diabetes patients.  Adrian Teo and Natasha Ng, the two scientific co-founders join to share the founding story.Learn more about BetaLife, Adrian, Natasha and the amazing work they are doing: BetaLife (Website)BetaLife (LinkedIn)Adrian Teo (LinkedIn)Natasha Ng (LinkedIn)Thank you for listening. If you like what you’ve heard, please share with a friend. After that, please subscribe and review us wherever you get your podcasts.Check out A*START CENTRAL (Website, LinkedIn)If you have future episode ideas, segments ideas or want to partner with us on this exciting journey, please get in touch: [email protected]

Ver todos los episodios